Research Essentials (Reported growth: Q4: 11.8%, 2007: 9.2%; Organic growth: Q4: 5.0%, 2007: 4.6%): Overall Q4 2007 organic sales growth paralleled that of the two preceding 2007 quarters, delivering results that beat long-term expectations for the third successive quarter and the year. Sales to pharmaceutical accounts in the U.S. and CAPLA remained strong in particular, as did overall sales to CAPLA customers. Customer centric marketing programs aimed at serving pharmaceutical customers and their contract research organizations wherever located around the globe continued to gain traction. Within Research Essentials' overall growth rate, the cell culture and lab essentials product initiatives were the major contributors to the Q4 2007 growth.
Research Biotech (Reported growth: Q4: 11.3%, 2007: 8.1%; Organic growth: Q4: 4.4%, 2007: 3.7%): As expected, improved sales growth at nearly a 6% rate over the final half of the year was driven by stronger spending by academic customers in Europe and by double-digit Q4 2007 growth in molecular biology and peptides products in both the U.S. and Europe. The addition of sales specialists earlier in the year and ongoing expansion of product offerings through internal development efforts and technology licenses contributed to this resurgent growth. Though pricing for synthetic DNA products remained consistent with that experienced in recent quarters, demand for oligos was down in both the U.S. and Japan during the fourth quarter, dampening this unit's otherwise reportable results.
SAFC (Fine Chemicals; Reported growth: Q4: 16.8%, 2007: 19.1%; Organic
growth: Q4: 3.2%, 2007: 7.1%
|SOURCE Sigma-Aldrich Corporation|
Copyright©2008 PR Newswire.
All rights reserved